Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Inivata Expects New Minimal Residual Disease, Recurrence Assay to Support Pharma Trials

Inivata Expects New Minimal Residual Disease, Recurrence Assay to Support Pharma Trials

Apr 23, 2020
|
John Gilmore
Premium

NEW YORK – Inivata has launched a patient-specific circulating-tumor DNA (ctDNA) assay for minimal residual disease (MRD) detection and cancer relapse monitoring, and anticipates offering the assay to biopharmaceutical companies for clinical cancer research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
23
Featured Webinar

Fluorescent Amplification for Next Generation Sequencing Library Preparation: A Streamlined Workflow to Improve NGS Quality Control Testing

Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

What's Popular?

In Cancer

  1. Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

  2. Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

  3. Grail Plans Additional Liquid Biopsy Tests for Cancer Detection, Monitoring

    Premium

  4. Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

    Premium

  5. NCI Awards InheRET $2M SBTT Grant to Improve Inherited Disease Detection

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.